Effects on suicidal risk: Comparison of clozapine to other newer medicines indicated to treat schizophrenia or bipolar disorder. (September 2021)
- Record Type:
- Journal Article
- Title:
- Effects on suicidal risk: Comparison of clozapine to other newer medicines indicated to treat schizophrenia or bipolar disorder. (September 2021)
- Main Title:
- Effects on suicidal risk: Comparison of clozapine to other newer medicines indicated to treat schizophrenia or bipolar disorder
- Authors:
- Forte, Alberto
Pompili, Maurizio
Imbastaro, Benedetta
De Luca, Gabriele Pasquale
Mastrangelo, Martina
Montalbani, Benedetta
Baldessarini, Ross J - Abstract:
- Background: Clozapine is the only treatment with regulatory-recognition of lowering suicidal risk, at least in schizophrenia patients. It remains uncertain whether such effects extend to other drugs for psychosis. Methods: We searched for reports on rates of suicidal behavior during treatment with clozapine and other modern drugs for psychosis (aripiprazole, olanzapine, risperidone, quetiapine, and ziprasidone) versus comparison or control treatments and analyzed the contrasts by random-effect meta-analysis to obtain pooled odds ratios (ORs) with 95% confidence intervals (CIs). Results: We identified 35 paired comparisons of modern drugs for psychosis versus comparison or control treatments in 18 reports. There was moderate overall superiority of all agents tested over alternatives (OR = 0.522, p = 0.004). With clozapine, this effect was large (OR = 0.229, p < 0.0001) and consistent (7/7 trials), but significant antisuicidal effects were not found with other drugs for psychosis in 28 other trials (OR = 0.941, p = 0.497). Apparent efficacy of specific agents ranked: risperidone ⩾ olanzapine ⩾ aripiprazole ⩾ ziprasidone ⩾ mixed drugs for psychosis ⩾ quetiapine, but none of these differences was significant. Conclusions: An ability of clozapine to reduce risk of suicides and attempts in schizophrenia patients appears to be a unique effect not shared with other modern medicines indicated for schizophrenia or bipolar disorder.
- Is Part Of:
- Journal of psychopharmacology. Volume 35:Number 9(2021)
- Journal:
- Journal of psychopharmacology
- Issue:
- Volume 35:Number 9(2021)
- Issue Display:
- Volume 35, Issue 9 (2021)
- Year:
- 2021
- Volume:
- 35
- Issue:
- 9
- Issue Sort Value:
- 2021-0035-0009-0000
- Page Start:
- 1074
- Page End:
- 1080
- Publication Date:
- 2021-09
- Subjects:
- Drugs for psychosis -- schizophrenia -- bipolar disorder -- suicide
Psychopharmacology -- Periodicals
615.78 - Journal URLs:
- http://jop.sagepub.com/ ↗
http://www.uk.sagepub.com/home.nav ↗ - DOI:
- 10.1177/02698811211029738 ↗
- Languages:
- English
- ISSNs:
- 0269-8811
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 16935.xml